FDA grants emergency use of malaria drugs against COVID-19The FDA has approved emergency use of malaria drugs championed by president Donald Trump for use in patients Share XFDA grants emergency use of malaria drugs against COVID-19https://pharmaphorum.com/news/fda-grants-emergency-use-of-malaria-drugs-against-covid-19/
UK court imposes safety rules on off-label use of Avastin in wet-AMDBayer has said a new UK court ruling could limit off-label use of Roche’s Avastin in ophthalmology by Share XUK court imposes safety rules on off-label use of Avastin in wet-AMDhttps://pharmaphorum.com/news/uk-appeal-court-upholds-use-of-avastin/
Trump pledges access to malaria drug chloroquine for COVID-19President Donald Trump thrust a decades old malaria drug called chloroquine into the forefront of efforts to treat Share XTrump pledges access to malaria drug chloroquine for COVID-19https://pharmaphorum.com/news/trump-pledges-access-to-malaria-drug-chloroquine-for-covid-19/
AZ picks up $350m after selling hypertension drugsAstraZeneca has picked up a $350m windfall after selling off five hypertension medicines to generics specialist Atnahs Pharma. Share XAZ picks up $350m after selling hypertension drugshttps://pharmaphorum.com/news/az-picks-up-350m-after-selling-hypertension-drugs/
Novartis’ Beovu safety woes could cost billions of dollars, says analystThe launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several Share XNovartis’ Beovu safety woes could cost billions of dollars, says analysthttps://pharmaphorum.com/news/novartis-beovu-launch-could-be-hit-by-safety-warning/
More pressure on Bayer as EU approves Novartis’ Beovu in wet AMDThe market for ophthalmology drugs in Europe just got hotter with the approval of Novartis’ Beovu for neovascular Share XMore pressure on Bayer as EU approves Novartis’ Beovu in wet AMDhttps://pharmaphorum.com/news/more-pressure-on-bayer-as-eu-approves-novartis-beovu-in-wet-amd/
Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from BayerThe UK’s cost-effectiveness agency has said it can’t recommend Bayer’s tumour-agnostic drug Vitrakvi for routine use on the Share XTumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayerhttps://pharmaphorum.com/news/tumour-agnostic-drugs-game-changing-says-nice-as-it-rejects-one-from-bayer/
AI specialist Exscientia signs drug discovery tie-up with BayerUK artificial intelligence company Exscientia has added another big pharma company to its partner roster, with Bayer seeking Share XAI specialist Exscientia signs drug discovery tie-up with Bayerhttps://pharmaphorum.com/news/ai-specialist-exscientia-signs-drug-discovery-tie-up-with-bayer/
SidekickHealth begins PAD partnership with BayerNordic digital therapeutics company SidekickHealth has begun a strategic partnership with German pharma Bayer to provide a digital Share XSidekickHealth begins PAD partnership with Bayerhttps://pharmaphorum.com/news/sidekickhealth-begins-pad-partnership-with-bayer/
